Fujisawa Pharmaceutical Co.

The majority of Fujisawa Pharmaceutical Co.'s revenue comes from the Japanese market, followed by the Americas. Royalty income accounts for a small portion of Astellas' total sales. Its largest therapeutic area by sales composition is oncology, followed by urology and transplantation. The company incorporates mergers and acquisitions as part of its long-term growth strategy. Astellas signs strategic partnerships and licensing agreements to strengthen its commercialization platform.